1. Home
  2. SRDX vs GBLI Comparison

SRDX vs GBLI Comparison

Compare SRDX & GBLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SRDX
  • GBLI
  • Stock Information
  • Founded
  • SRDX 1979
  • GBLI 2016
  • Country
  • SRDX United States
  • GBLI United States
  • Employees
  • SRDX N/A
  • GBLI N/A
  • Industry
  • SRDX Medical/Dental Instruments
  • GBLI Property-Casualty Insurers
  • Sector
  • SRDX Health Care
  • GBLI Finance
  • Exchange
  • SRDX Nasdaq
  • GBLI Nasdaq
  • Market Cap
  • SRDX 415.4M
  • GBLI 484.5M
  • IPO Year
  • SRDX 1998
  • GBLI 2003
  • Fundamental
  • Price
  • SRDX $31.10
  • GBLI $30.39
  • Analyst Decision
  • SRDX Buy
  • GBLI
  • Analyst Count
  • SRDX 2
  • GBLI 0
  • Target Price
  • SRDX $43.00
  • GBLI N/A
  • AVG Volume (30 Days)
  • SRDX 89.7K
  • GBLI 1.7K
  • Earning Date
  • SRDX 07-30-2025
  • GBLI 08-06-2025
  • Dividend Yield
  • SRDX N/A
  • GBLI 4.62%
  • EPS Growth
  • SRDX N/A
  • GBLI N/A
  • EPS
  • SRDX N/A
  • GBLI 1.99
  • Revenue
  • SRDX $121,575,000.00
  • GBLI $437,447,000.00
  • Revenue This Year
  • SRDX N/A
  • GBLI $7.67
  • Revenue Next Year
  • SRDX $3.70
  • GBLI $7.93
  • P/E Ratio
  • SRDX N/A
  • GBLI $15.22
  • Revenue Growth
  • SRDX N/A
  • GBLI N/A
  • 52 Week Low
  • SRDX $26.00
  • GBLI $26.94
  • 52 Week High
  • SRDX $42.25
  • GBLI $37.00
  • Technical
  • Relative Strength Index (RSI)
  • SRDX 66.72
  • GBLI 44.43
  • Support Level
  • SRDX $30.54
  • GBLI $30.00
  • Resistance Level
  • SRDX $31.47
  • GBLI $33.25
  • Average True Range (ATR)
  • SRDX 0.93
  • GBLI 0.67
  • MACD
  • SRDX 0.21
  • GBLI -0.24
  • Stochastic Oscillator
  • SRDX 95.58
  • GBLI 9.75

About SRDX Surmodics Inc.

Surmodics Inc is a provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic (IVD) immunoassay tests and microarrays. The company's reportable segments are; Medical Device and In Vitro Diagnostics. Maximum revenue for the company is derived from its Medical Device segment which is involved in the manufacturing and licensing of performance coatings, including surface modification coating technologies and drug-delivery coating technologies. This segment also manufactures vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. Geographically, the company derives key revenue from its domestic market.

About GBLI Global Indemnity Group LLC (DE)

Global Indemnity Group LLC provides both admitted and non-admitted specialty property and casualty insurance coverages and individual policyholder coverages in the United States, as well as reinsurance world-wide. The company's two segments are: Penn-America and Non-Core Operations. The Penn-America segment offers specialty property and casualty products designed for its Wholesale Commercial, Specialty Products, InsurTech, and Assumed Reinsurance product offerings. These product lines are offered in the excess and surplus lines marketplace; and Non-Core Operations segment contains lines of business that have been de-emphasized or are no longer being written. The majority of its revenue is from the the Penn-America segment . Geographically, the majority is from California.

Share on Social Networks: